{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:39:12Z","timestamp":1790271552126,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,7,7]],"date-time":"2017-07-07T00:00:00Z","timestamp":1499385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["681137"],"award-info":[{"award-number":["681137"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["EAVI2020"],"award-info":[{"award-number":["EAVI2020"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["009\/JTC 2013"],"award-info":[{"award-number":["009\/JTC 2013"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009060","name":"Sidaction","doi-asserted-by":"publisher","award":["10800\/2016"],"award-info":[{"award-number":["10800\/2016"]}],"id":[{"id":"10.13039\/100009060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EBioMedicine"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.ebiom.2017.07.007","type":"journal-article","created":{"date-parts":[[2017,7,11]],"date-time":"2017-07-11T05:14:43Z","timestamp":1499750083000},"page":"122-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Neutralizing Antibodies Against a Specific Human Immunodeficiency Virus gp41 Epitope are Associated With Long-term Non-progressor Status"],"prefix":"10.1016","volume":"22","author":[{"given":"Olivier","family":"Lucar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Potard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assia","family":"Samri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Autran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Moog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Debr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9362-3922","authenticated-orcid":false,"given":"Vincent","family":"Vieillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2017.07.007_bb0005","doi-asserted-by":"crossref","first-page":"316","DOI":"10.4161\/hv.4.4.5751","article-title":"Protective immunity following vaccination: how is it defined?","volume":"4","author":"Amanna","year":"2008","journal-title":"Hum. Vaccin."},{"key":"10.1016\/j.ebiom.2017.07.007_bb0010","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/nature12744","article-title":"Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys","volume":"503","author":"Barouch","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2017.07.007_bb0015","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ebiom.2016.08.045","article-title":"Amino acid changes in the HIV-1 gp41 membrane proximal region control virus neutralization sensitivity","volume":"12","author":"Bradley","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ebiom.2017.07.007_bb0020","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/(SICI)1096-9071(199907)58:3<256::AID-JMV11>3.0.CO;2-Z","article-title":"Status of long-term asymptomatic HIV-1 infection correlates with viral load but not with virus replication properties and cell tropism. French ALT study group","volume":"58","author":"Candotti","year":"1999","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ebiom.2017.07.007_bb0025","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1097\/00002030-199813000-00005","article-title":"Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection","volume":"12","author":"Carotenuto","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.ebiom.2017.07.007_bb0030","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2017.07.007_bb0035","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1086\/314773","article-title":"A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects","volume":"179","author":"Cecilia","year":"1999","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ebiom.2017.07.007_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044163","article-title":"Human immunodeficiency virus type-1 (HIV-1) continues to evolve in presence of broadly neutralizing antibodies more than ten years after infection","volume":"7","author":"Chaillon","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ebiom.2017.07.007_bb0045","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nbt.2167","article-title":"A proteomics approach for the identification and cloning of monoclonal antibodies from serum","volume":"30","author":"Cheung","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ebiom.2017.07.007_bb0050","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1128\/JVI.01482-09","article-title":"Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables","volume":"84","author":"Doria-Rose","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.ebiom.2017.07.007_bb0055","doi-asserted-by":"crossref","first-page":"14169","DOI":"10.1128\/JVI.79.22.14169-14178.2005","article-title":"Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment","volume":"79","author":"Emu","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.ebiom.2017.07.007_bb0060","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1086\/651144","article-title":"Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression","volume":"201","author":"Euler","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ebiom.2017.07.007_bb0065","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal2144","article-title":"Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller","volume":"9","author":"Freund","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ebiom.2017.07.007_bb0070","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0005-2736(03)00161-5","article-title":"The HIV Env-mediated fusion reaction","volume":"1614","author":"Gallo","year":"2003","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ebiom.2017.07.007_bb0075","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1128\/JVI.02622-09","article-title":"Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors","volume":"84","author":"van Gils","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.ebiom.2017.07.007_bb0080","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1097\/QAD.0b013e32832b44c8","article-title":"Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French hospital database on HIV","volume":"23","author":"Grabar","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.ebiom.2017.07.007_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036438","article-title":"International network for comparison of HIV neutralization assays: the NeutNet report II","volume":"7","author":"Heyndrickx","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ebiom.2017.07.007_bb0090","doi-asserted-by":"crossref","first-page":"6274","DOI":"10.4049\/jimmunol.173.10.6274","article-title":"Involvement of Fc gamma RI (CD64) in the mechanism of HIV-1 inhibition by polyclonal IgG purified from infected patients in cultured monocyte-derived macrophages","volume":"173","author":"Holl","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.ebiom.2017.07.007_bb0095","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1128\/JVI.02625-05","article-title":"Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells","volume":"80","author":"Holl","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.ebiom.2017.07.007_bb0100","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/QAD.0000000000000106","article-title":"Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection","volume":"28","author":"Hraber","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.ebiom.2017.07.007_bb0105","first-page":"58","article-title":"Long-term non-progression and broad HIV-1-specific proliferative T-cell responses","volume":"24","author":"Imami","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ebiom.2017.07.007_bb0110","doi-asserted-by":"crossref","first-page":"10557","DOI":"10.1128\/JVI.77.19.10557-10565.2003","article-title":"Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1","volume":"77","author":"Labrijn","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.ebiom.2017.07.007_bb0115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00042560-200205010-00005","article-title":"Impact of suppression of viral replication by highly active antiretroviral therapy on immune function and phenotype in chronic HIV-1 infection","volume":"30","author":"Lange","year":"2002","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.ebiom.2017.07.007_bb0120","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1128\/JVI.02098-13","article-title":"Both HLA-B*57 and plasma HIV RNA levels contribute to the HIV-specific CD8+ T cell response in HIV controllers","volume":"88","author":"L\u00e9curoux","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.ebiom.2017.07.007_bb0125","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1038\/srep05845","article-title":"Neutralizing antibodies inhibit HIV-1 infection of plasmacytoid dendritic cells by an Fc\u03b3RIIa independent mechanism and do not diminish cytokines production","volume":"4","author":"Lederle","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.ebiom.2017.07.007_bb0130","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1126\/science.aad2450","article-title":"Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer","volume":"351","author":"Lee","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2017.07.007_bb0135","doi-asserted-by":"crossref","first-page":"15614","DOI":"10.1073\/pnas.1413550111","article-title":"Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development","volume":"111","author":"Lewis","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ebiom.2017.07.007_bb0140","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1126\/science.aag0491","article-title":"Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus","volume":"353","author":"Liu","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2017.07.007_bb0145","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1126\/science.aaf1279","article-title":"Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo","volume":"352","author":"Lu","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2017.07.007_bb0150","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.V93.3.936","article-title":"Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the long-term nonprogressor status in human immunodeficiency virus-1-infected individuals","volume":"93","author":"Magierowska","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2017.07.007_bb0155","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1086\/430320","article-title":"Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression","volume":"191","author":"Martinez","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ebiom.2017.07.007_bb0160","doi-asserted-by":"crossref","first-page":"13878","DOI":"10.1073\/pnas.251539598","article-title":"High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation","volume":"98","author":"McNeil","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ebiom.2017.07.007_bb0165","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/ni.3161","article-title":"Success and failure of the cellular immune response against HIV-1","volume":"16","author":"Migueles","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ebiom.2017.07.007_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/8b3b24b5-d4ed-483a-b233-0a88513ad499","article-title":"Characteristics of the earliest cross-neutralizing antibody response to HIV-1","volume":"7","author":"Mikell","year":"2011","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ebiom.2017.07.007_bb0175","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nature13808","article-title":"Structure and immune recognition of trimeric pre-fusion HIV-1 Env","volume":"514","author":"Pancera","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2017.07.007_bb0180","doi-asserted-by":"crossref","first-page":"7397","DOI":"10.1128\/JVI.00656-09","article-title":"Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41","volume":"83","author":"Perez","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.ebiom.2017.07.007_bb0185","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1128\/JVI.00278-13","article-title":"Antibody-DEPENDENT, Fc\u03b3RI-mediated neutralization of HIV-1 in TZM-bl cells occurs independently of phagocytosis","volume":"87","author":"Perez","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.ebiom.2017.07.007_bb0190","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1093\/cid\/cit335","article-title":"A single amino-acid change in a highly conserved motif of gp41 elicits HIV-1 neutralization and protects against CD4 depletion","volume":"57","author":"Petitdemange","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ebiom.2017.07.007_bb0195","doi-asserted-by":"crossref","first-page":"10269","DOI":"10.1128\/JVI.01149-09","article-title":"Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression","volume":"83","author":"Piantadosi","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.ebiom.2017.07.007_bb0200","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1097\/QAD.0b013e32835f6b30","article-title":"Polymorphism in gp41glycoprotein might influence the progression to disease in HIV-1 infection","volume":"27","author":"Potard","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.ebiom.2017.07.007_bb0205","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1128\/JVI.74.12.5403-5411.2000","article-title":"Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes","volume":"74","author":"Ruppach","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.ebiom.2017.07.007_bb0210","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-med-091014-090749","article-title":"Broadly neutralizing antibodies against HIV: new insights to inform vaccine design","volume":"67","author":"Sadanand","year":"2016","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ebiom.2017.07.007_bb0215","doi-asserted-by":"crossref","first-page":"6776","DOI":"10.1073\/pnas.0611244104","article-title":"HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype","volume":"104","author":"S\u00e1ez-Ciri\u00f3n","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ebiom.2017.07.007_bb0220","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11904-016-0299-7","article-title":"Broadly neutralizing antibodies for HIV eradication","volume":"13","author":"Stephenson","year":"2016","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"10.1016\/j.ebiom.2017.07.007_bb0225","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3389\/fimmu.2014.00289","article-title":"Which antibody functions are important for an HIV vaccine?","volume":"5","author":"Su","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ebiom.2017.07.007_bb0230","doi-asserted-by":"crossref","first-page":"10981","DOI":"10.1073\/pnas.0504315102","article-title":"NK cytotoxicity against CD4+ T cells during HIV-1 infection: a gp41 peptide induces the expression of an NKp44 ligand","volume":"102","author":"Vieillard","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ebiom.2017.07.007_bb0235","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1097\/01.aids.0000244198.65263.17","article-title":"Specific adaptive humoral response against a gp41 motif inhibits CD4 T-cell sensitivity to NK lysis during HIV-1 infection","volume":"20","author":"Vieillard","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.ebiom.2017.07.007_bb0240","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1073\/pnas.0711629105","article-title":"A vaccine strategy against AIDS: an HIV gp41 peptide immunization prevents NKp44L expression and CD4+ T cell depletion in SHIV-infected macaques","volume":"105","author":"Vieillard","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ebiom.2017.07.007_bb0245","doi-asserted-by":"crossref","first-page":"6883","DOI":"10.1016\/j.vaccine.2012.09.004","article-title":"An HIVgp41 vaccine protects CD4 central memory T cells in SHIV-infected macaques","volume":"30","author":"Vieillard","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.ebiom.2017.07.007_bb0250","doi-asserted-by":"crossref","first-page":"38946","DOI":"10.18632\/oncotarget.7793","article-title":"Perspectives for immunotherapy: which applications might achieve an HIV functional cure?","volume":"7","author":"Vieillard","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ebiom.2017.07.007_bb0255","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.cell.2014.01.052","article-title":"Structural insights on the role of antibodies in HIV-1 vaccine and therapy","volume":"156","author":"West","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2017.07.007_bb0260","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/ni889","article-title":"Lineage relationship and protective immunity of memory CD8 T cell subsets","volume":"4","author":"Wherry","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ebiom.2017.07.007_bb0265","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1073\/pnas.1213737110","article-title":"Molecular deconvolution of the monoclonal antibodies that comprise the polyclonal serum response","volume":"110","author":"Wine","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ebiom.2017.07.007_bb0270","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1126\/science.280.5371.1884","article-title":"The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens","volume":"280","author":"Wyatt","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2017.07.007_bb0275","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1097\/QAD.0b013e32833e5009","article-title":"Distinct differentiation profiles of HIV-Gag and Nef-specific central memory CD8+ T cells associated with HLA-B57\/5801 and virus control","volume":"24","author":"Xie","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.ebiom.2017.07.007_bb0280","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1074-7613(00)00006-6","article-title":"Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities","volume":"13","author":"Xu","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.ebiom.2017.07.007_bb0285","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3389\/fimmu.2014.00250","article-title":"Immunologic basis for long HCDR3s in broadly neutralizing antibodies against HIV-1","volume":"5","author":"Yu","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ebiom.2017.07.007_bb0290","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1006\/viro.1996.8300","article-title":"Plasmas from lymphocyte- and macrophage-tropic SIVmac-infected macaques have antibodies with a broader spectrum of virus neutralization activity in macrophage versus lymphocyte cultures","volume":"227","author":"Zhuge","year":"1997","journal-title":"Virology"}],"container-title":["EBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396417302797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396417302797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T18:46:46Z","timestamp":1762454806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396417302797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":58,"alternative-id":["S2352396417302797"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2017.07.007","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neutralizing Antibodies Against a Specific Human Immunodeficiency Virus gp41 Epitope are Associated With Long-term Non-progressor Status","name":"articletitle","label":"Article Title"},{"value":"EBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2017.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}